We are looking forward to sharing these exciting new advances with our customers.” Woody continued, “We will also present educational seminars at the conference on topics including, How our leading clinical product line, Theraworx®, can be your partner eliminating Catheter-Associated Urinary Tract Infections (CAUTI) The story of a journey to ZERO CAUTI through Theraworx® products A case study of reducing skin infections at a major university wrestling team with Theraworx® bathing protocol and A Theraworx® operational cost analysis for foley catheter insertion and maintenance. This Pathogenesis-Based Therapy is being recognized by clinical thought leaders nationwide and is rapidly gaining acceptance with Acute Care and Long-Term Care communities.” We believe that optimizing the permeability barrier by managing the pH is primary to restoring dermal breakdown in patients suffering with IAD. The unique mechanism of action of our Theraworx® products optimizes the outer layer of the skin, the Stratum Corneum. The incidence in Acute Care is even larger with an estimated total of 3.5 million patients affected in our health system at any one time. alone, it is believed that 70% of the long term care community has fecal and urinary incontinence and 43% have IAD. Reports from wound specialists across the country are confirming our belief. Our formulation closely matches the ‘ideal’ product characteristics. The International consortium calls for new innovative approaches in the treatment of IAD with multiple mechanisms of action. Stephen Woody, Chairman and CEO, stated, “According to proceedings from Global IAD Expert Panel and published in Wounds International Best Practice Principles, IAD represents a significant health challenge world-wide and is a recognized risk factor in pressure ulcer development. Avadim will also host four educational sessions at the Conference focused on its patented Theraworx® products and patent-pending protocols which have demonstrated a proven ability to help hospitals control hospital-acquired conditions. (“Avadim”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue, announced today that it will launch its new therapy for Incontinence Associated Dermatitis (“IAD”), skin damage associated with exposure to urine or stool, at the 43rd Annual APIC (Association for Professionals in Infection Control and Epidemiology) Conference. Theraworx® Featured in Four Educational Seminars at the Largest Infection Prevention Conference in the WorldĪsheville, NC (May 18, 2016) – Avadim Technologies, Inc.
0 kommentar(er)
